Help For Irritable Bowel Syndrome (IBS) - Education, Support, & Self Help for Irritable Bowel Syndrome
Heather & Company View Cart
Shop for IBSIBS Message BoardsIBS News & ReviewsStore Finder
IBS Diet & Recipes
IBS Books
IBS Supplements
Yoga for IBS
Hypnosis for IBS
Tummy Teas
Get The IBS Diet Cheat Sheet
Get Trigger Foods, Safe Foods, Ten Commandments of Eating for IBS, More!

Enter First Name:

Enter Email:

We value your privacy

All Boards >> Irritable Bowel Syndrome Research Library


Reged: 12/09/02
Posts: 7677
Loc: Seattle, WA
Irritable Bowel Syndrome - An Evidence-Based Approach to Diagnosis
      06/27/04 01:14 PM

From Alimentary Pharmacology & Therapeutics

Irritable Bowel Syndrome - An Evidence-Based Approach to Diagnosis

Posted 06/21/2004

B.D. Cash; W.D. Chey

Summary and Introduction
Irritable bowel syndrome (IBS) represents one of the most common reasons for primary care visits and consultation with a gastroenterologist. It is characterized by abdominal discomfort, bloating and disturbed defecation in the absence of any identifiable physical, radiologic or laboratory abnormalities indicative of organic gastrointestinal disease. IBS is a costly disorder, responsible for significant direct and indirect costs to patients and society. Much of the cost attributed to IBS arises from the time and resources used to establish the diagnosis. Historically IBS has been viewed by many as a diagnosis of exclusion rather than as a primary diagnosis, and many patients with typical symptoms will undergo an extensive array of diagnostic tests and procedures prior to the eventual diagnosis of IBS.

Recent reviews addressing the management of such patients have cast doubt on the necessity for this degree of testing. Current best evidence does not support the routine use of blood tests, stool studies, breath tests, abdominal imaging or lower endoscopy in order to exclude organic gastrointestinal disease in patients with typical IBS symptoms without alarm features. Serological testing for celiac sprue in this population may eventually prove useful but validation of studies indicating an increased prevalence of this disease in patients with suspected IBS is needed.

The development and refinement of symptom-based criteria defining the clinical syndrome of IBS has greatly facilitated the diagnosis of this condition, which can be confidently diagnosed through the identification of typical symptoms, normal physical examination and the exclusion of alarm features. The presence of alarm features or persistent non-response to symptom-directed therapies should prompt a more detailed diagnostic evaluation dictated by the patient's predominant symptoms.

Irritable bowel syndrome (IBS) is a chronic gastrointestinal condition characterized by abdominal discomfort, bloating and disturbed defecation. It is considered one of a group of functional gastrointestinal disorders in which a variety of factors including altered motility, abnormal visceral sensation and psychosocial factors interplay to cause symptoms. By definition, IBS is characterized by the absence of any identifiable physical, radiologic or laboratory abnormalities indicative of organic disease. IBS is a common condition, with prevalence estimates ranging between 7 and 24% in women and between 5 and 19% in men in the United States and Britain.[1-3] The symptoms of IBS represent one of the most common reasons for primary care visits, and consultation with a gastroenterologist accounting for 2.4-3.5 million physician visits per year.[1,4] Patients with IBS visit their physicians more frequently than those without IBS for both GI-related and non-GI-related problems, reflecting the increased likelihood of a variety of other conditions such as migraine headache, fibromyalgia and chronic pelvic pain.[5,6]

Based upon these observations, it should come as no surprise that the annual economic consequences of IBS in the United States are substantial. It has been estimated that IBS accounts for $1.7-10 billion in annual direct medical costs in the USA.[7,8] Perhaps more importantly, an additional $10-20 billion in indirect costs, largely resulting from work absenteeism and decreased productivity, has been attributed to IBS.[8,9] These estimates do not include prescription or over the counter-medications for IBS, so it is likely that a substantial portion of these costs may be attributed to the diagnostic testing that is frequently conducted as part of the evaluation of patients with suspected IBS. This paper will examine the current recommendations for the diagnostic evaluation of patients with suspected IBS and will critically review the evidence regarding the yield of various diagnostic tests and procedures that are routinely performed in this group of patients in order to exclude organic disease.


Section 1 of 5 Next Page: Evidence-Based Medicine Approach to Diagnosis

Click here to read this entire article

B.D. Cash* & W.D. Chey†

*Division of Gastroenterology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; †Division of Gastroenterology, University of Michigan School of Medicine, Ann Arbor, MI, USA

Aliment Pharmacol Ther 19(12):1235-1245, 2004. © 2004 Blackwell Publishing

Heather is the Administrator of the IBS Message Boards. She’s the author of Eating for IBS and The First Year: IBS, and the CEO of Heather's Tummy Care. Join her IBS Newsletter. Meet Heather on Facebook!

Post Extras Print Post   Remind Me!     Notify Moderator

Entire thread
Subject Posted by Posted on
* General IBS / Bowel Dysfunction HeatherAdministrator 07/14/03 01:56 PM
. * April is IBS Awareness Month: 10 recent advances in research, diagnostics HeatherAdministrator   04/16/18 02:05 PM
. * Bacteria can trigger stomach cancer HeatherAdministrator   08/25/17 04:11 PM
. * Fecal microbiota transplantation improved symptoms and quality of life in patients with IBS HeatherAdministrator   05/09/17 01:28 PM
. * Autism symptoms improve after fecal transplant, small study finds HeatherAdministrator   01/26/17 02:54 PM
. * Microbiota and arthritis: correlations or cause? HeatherAdministrator   02/19/16 01:09 PM
. * Takeda, Enterome to collaborate on microbiome-based drugs f